Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Posts Higher Q1 Revenues, Enters Black After Aclara Lawsuit Resolved

NEW YORK, April 30 – Caliper Technologies of Mountain View, Calif., said Monday its first-quarter revenues surged as a result of increased licensing fees and product sales.

The company, which makes lab-on-a-chip technology, said its first quarter revenues increased to $9.8 million, compared with $3.9 million a year ago. Caliper attributed $5 million of the increase to fees garnered from licensing patents to Aclara Biosciences.The remaining increase stemmed from a commercial collaboration with Agilent Technologies.

"In this quarter, licensing revenue increased as a component of our overall revenue, consistent with our strategy to expand our revenue sources,” Jim Knighton, Caliper’s chief financial officer, said in a statement.

“Revenue from technology access program customers in the form of licensing and subscription fees and chip and instrument purchases, as well as product sales of the Agilent 2100 Bioanalyzer and R&D funding from Agilent were the other major revenue contributors,” he said.

The company said that sales in the US, Europe, and Japan grew. In addition, Agilent has recently initiated a sales effort in China, Taiwan, Korea and Australia, which are expected to help boost Caliper’s sales.

Increased research and development activity drove operating expenses up $2.5 million to $13.8 million in the first quarter of the year.

For the quarter, Caliper posted net income of $26.4 million, or $1.03 a diluted share, including one-time gains, compared with net losses of $8.3 million, or 40 cents a diluted share, in the year ago period. 

In the first quarter, the company posted $27.5 million, or $1.07 a diluted share, for the dismissal of all suits and countersuits with Aclara. Not including these gains, Caliper would have posted net losses of $1.1 million, or five cents a diluted share. 

The company had $184.2 million at the end of the quarter in cash and investments. The company also posted $32.5 million in other assets, reflecting the guaranteed value of the shares of Aclara’s stock Caliper received as part of a settlement from a legal dispute.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.